Skip to content
Peptide research

P21

Also known as P021 · Neurotrophic Peptide
Category
Brain & Cognition
Administration routes
Injectable
Regulatory status
Not FDA-approved

What it is

A synthetic CNTF-derived peptide marketed for cognitive enhancement and neuroprotection. The case rests entirely on animal studies of memory rescue and reduced tau and amyloid buildup; touted uses in macular degeneration and rare neurodevelopmental disorders remain speculative. There is no human safety data, and boosting neurogenesis carries a theoretical risk of uncontrolled cell growth. Not an approved drug; supply is unregulated research-grade material.

Read Full record

Studied uses & evidence

Studied uses(7)

  • Rescues cognitive deficits and enhances learning and memory

    Low

    Extensive rodent studies show learning and memory gains; no human trials exist yet.

  • Reduces abnormal tau hyperphosphorylation and neurofibrillary pathology

    Low

    Multiple rodent studies show reduced tau pathology via a defined mechanism; no human data yet.

  • Reduces amyloid-beta plaque pathology

    Low

    Animal studies show mixed results, with amyloid reduction seen only in one lab's model.

Evidence limits

Evidence Level
Preclinical Only

All evidence for P021 comes from in vitro and in vivo animal studies. No human clinical trials (Phase 1, 2, or 3) have been published or registered on ClinicalTrials.gov as of March 2026. Preclinical work spans several animal models (3xTg-AD mice, aged Fisher rats, Ts65Dn Down syndrome mice, Cdkl5 KO mice), treatment paradigms (therapeutic, preventive, developmental), and endpoints (cognition, tau/Abeta pathology, neurogenesis, synaptic markers, MRI microstructure), but findings vary by model: the CDKL5 mouse study did not reproduce the BDNF or neuroanatomical benefits reported in other animal models. Long-term administration (up to 18 months in mice) has shown no adverse effects including no weight loss, tumors, or pain. However, the absence of any human data means efficacy and safety in humans remain entirely unestablished.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Risk summary(5)

Risks = level of concern: High · Moderate · Low · Theoretical

  • No established human safety profile

    High
  • Potential for uncontrolled neurogenesis or cellular proliferation

    Theoretical
  • Potential antibody formation

    Theoretical
  • Contraindicated populations (theoretical)

    Theoretical
  • Research chemical quality and purity concerns

    High
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.